Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 4/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699774 | 0.87 | CHRM4 (0.42) | ABCC1PIK3CDMTORPIK3CGOPRK1 | |
| SCHEMBL20599223 | 0.81 | RBP4 (0.41) | ALDH1A1SMN1; SMN2PKMSPRVNN1 | |
| SCHEMBL17674350 | 0.80 | OGA (0.38) | PIK3CAVNN1OPRK1 | |
| SCHEMBL17845850 | 0.74 | VNN1 (0.40) | ALDH1A1SMN1; SMN2VNN1OPRK1 | |
| SCHEMBL20619561 | 0.73 | VNN1 (0.39) | ALDH1A1SPRVNN1LRRK2OPRK1 | |
| SCHEMBL17675419 | 0.72 | OPRK1 (0.36) | OPRK1 | |
| SCHEMBL20599108 | 0.72 | GAK (0.42) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL20598365 | 0.71 | KMT2A (0.51) | ALDH1A1SMN1; SMN2VNN1KDM4EL3MBTL1 | |
| SCHEMBL19499573 | 0.71 | MMP2 (0.43) | ALDH1A1SMN1; SMN2PIK3CAPKMLRRK2 | |
| SCHEMBL19454416 | 0.70 | VNN1 (0.33) | VNN1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | ABCC1 2160/4885ALDH1A1 721/4885PIK3CD 2205/4885 |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | ABCC1 2160/4885ALDH1A1 721/4885PIK3CD 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.